Supplementary material-Dargaud___Supplemental_Material_02_03_2020.docx (34.94 kB)
Download file

Supplementary Material for: Eltrombopag for the Treatment of Severe Inherited Thrombocytopenia

Download (34.94 kB)
posted on 28.09.2020, 12:49 by Abdelmoumen K., Fabre M., Ducastelle-Lepretre S., Favier R., Ballerini P., Bordet J.C., Dargaud Y.
Inherited thrombocytopenias correspond to a group of hereditary disorders characterized by a reduced platelet count, platelet dysfunction, and a family history of thrombocytopenia. It is commonly associated with mucocutaneous bleeding. Thrombocytopenia results from mutations in genes involved in megakaryocyte differentiation, platelet formation, and clearance. Here we report on a patient presenting with severe syndromic inherited thrombocytopenia manifesting as spontaneous mucocutaneous bleeds, requiring frequent platelet transfusions. Thrombocytopenia was explained by the presence of 4 mutations in 3 hematopoietic transcription factor genes: FLI1, RUNX1, and ETV6. The patient was successfully treated with high-dose eltrombopag at 150 mg/day, an orally available non-peptide thrombopoietin receptor agonist. Since the start of treatment 23 months ago, the manifestations of bleeding have resolved, and no platelet transfusions or corticosteroids have been required. The patient has no clinical or laboratory evidence of myeloid malignancy so far.


Usage metrics